Phathom Pharmaceuticals, Inc.
PHATBiotechnology
$5.74−7.72%As of Oct 30vs prior close
- Market cap
- $466.6M
- P/E (TTM)
- –
- From 52W high
- −68.25%
- EPS (LTM)
- -$1.00
- Revenue (LTM)
- $274.9M
- Net margin
- -30.19%
- Dividend yield
- 0.00%
Nomior Score
46
Patient ValueSpeculativeBottom 40% of the scored universe
Growth71
Quality59
Value67
Momentum9
Resilience36
Growth
$274.9Mrevenue, LTM
FY22 $0LTM $274.9M
Connections
Revenue to profitQ3 FY26
Who owns it
2funds